Astrazeneca Pharma India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve the Un-audited Financial Results of the Company for the quarter and half year ended September 30, 2026. We also confirm that the 'Trading Window' remains closed for all Designated Persons, from September 16, 2026 to November 7, 2026 (both days inclusive) in terms of AstraZeneca Pharma ....

October 30, 2026 The Manager - Listing National Stock Exchange of India Ltd. Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai - 400051 The Manager - Listing BSE Limited P J Towers, Dalal Street, Fort, Mumbai - 400001 Dear Sir/ Madam, Sub: Meeting of the Board of Directors of the Company to be held on Thursday, November 5, 2026 Ref: Scrip Code – BSE: 506820, NSE: ASTRAZEN This is to inform that a meeting of the Board of Directors of AstraZeneca Pharma India Limited will be held on Thursday, November 5, 2026 inter alia to consider and approve the Un-audited Financial Results of the Company for the quarter and half year ended September 30, 2026. We also confirm that the ‘Trading Window’ remains closed for all Designated Persons, from September 16, 2026 to November 7, 2026 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015. We request you to please take the same on record. Thanking you, For AstraZeneca Pharma India Limited Tanya Sanish Company Secretary & Compliance Officer ACS No.: A25784